<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47360/1995-4484-2021-411-417</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-3058</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Кальцификация коронарных артерий у пациентов с болезнью депонирования кристаллов пирофосфата кальция и остеоартритом коленных суставов</article-title><trans-title-group xml:lang="en"><trans-title>Calcification of coronary arteries in patients with calcium pyrophosphate crystal deposition disease and knee osteoarthritis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1191-5831</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Елисеев</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Eliseev</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Российская Федерация, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>115522, Russian Federation, Moscow, Kashirskoye Highway, 34A</p></bio><email xlink:type="simple">elicmax@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0840-1549</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новикова</surname><given-names>Д. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Novikova</surname><given-names>D. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>111123, Российская Федерация, Москва, шоссе Энтузиастов, 86</p></bio><bio xml:lang="en"><p>111123, Russian Federation, Moscow, Entuziastov Highway, 86</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3667-722X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новикова</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Novikova</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Российская Федерация, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>115522, Russian Federation, Moscow, Kashirskoye Highway, 34A</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4503-7750</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бланк</surname><given-names>Л. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Blank</surname><given-names>L. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Российская Федерация, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>115522, Russian Federation, Moscow, Kashirskoye Highway, 34A</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5394-7869</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Желябина</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhelyabina</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Российская Федерация, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>115522, Russian Federation, Moscow, Kashirskoye Highway, 34A</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3246-1157</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черкасова</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Cherkasova</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Российская Федерация, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>115522, Russian Federation, Moscow, Kashirskoye Highway, 34A</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1598-8360</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Насонов</surname><given-names>Е. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Nasonov</surname><given-names>E. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Российская Федерация, Москва, Каширское шоссе, 34а</p><p>119991, Российская Федерация, Москва, ул. Трубецкая, 8, стр. 2</p></bio><bio xml:lang="en"><p>115522, Russian Federation, Moscow, Kashirskoye Highway, 34A</p><p>119991, Russian Federation, Moscow, Trubetskaya str., 8, building 2</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБУЗ г. Москвы Московский клинический научно-практический центр им. А.С. Логинова Департамента здравоохранения г. Москвы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>The Loginov Moscow Clinical Scientific Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>05</day><month>09</month><year>2021</year></pub-date><volume>59</volume><issue>4</issue><elocation-id>411–417</elocation-id><permissions><copyright-statement>Copyright &amp;#x00A9; Елисеев М.С., Новикова Д.С., Новикова А.М., Бланк Л.М., Желябина О.В., Черкасова М.В., Насонов Е.Л., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Елисеев М.С., Новикова Д.С., Новикова А.М., Бланк Л.М., Желябина О.В., Черкасова М.В., Насонов Е.Л.</copyright-holder><copyright-holder xml:lang="en">Eliseev M.S., Novikova D.S., Novikova A.M., Blank L.M., Zhelyabina O.V., Cherkasova M.V., Nasonov E.L.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/3058">https://rsp.mediar-press.net/rsp/article/view/3058</self-uri><abstract><p>Частота сосудистой кальцификации у пациентов с остеоартритом (ОА) и болезнью депонирования кристаллов пирофосфата кальция (БДПК) в настоящий момент не изучена; также не известно, какую роль играют кристаллы кальция (основные и пирофосфаты) в развитии коронарной кальцификации.</p><p>Цель исследования – определить у пациентов с болезнью депонирования кристаллов пирофосфата кальция и остеоартритом коленных суставов, не имеющих клинических признаков сердечно-сосудистых заболеваний, частоту и степень кальцификации коронарных сосудов.</p><sec><title>Материалы и методы</title><p>Материалы и методы. Одномоментное, одноцентровое исследование, выполнено методом «случай – контроль». Основная группа – 20 пациентов с БДПК; группа сравнения – 20 пациентов с ОА коленных суставов. Критерии включения: возраст от 18 до 65 лет; отсутствие клинических признаков сердечно-сосудистых заболеваний на момент осмотра и указаний на сердечно-сосудистые катастрофы в анамнезе. Критерии исключения: отсутствие подписанного информированного согласия; беременность; кормление грудью; другое ревматическое заболевание; онкопатология; высокий и очень высокий сердечно-сосудистый риск по шкале SCORE. Обследование включало оценку антропометрических данных, артериального давления, липидного профиля, сывороточных уровней глюкозы, креатинина, мочевой кислоты, С-реактивного белка, витамина D, остеопротегерина, паратгормона, магния, фосфора, общего кальция. Всем пациентам проводилась мультиспиральная компьютерная томография с определением коронарного кальциевого счета (КC) и количества пораженных артерий. Для вычисления КC использовалась методика A.S. Agatston и соавт.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Большинство параметров в сравниваемых группах не различались. При оценке кальцификации коронарных артерий по индексу A.S. Agatston и соавт. 9 (45%) пациентов с БДПК и 8 (40%) пациентов с ОА имели КC&gt;1. Значения КC соответствовали стенозу коронарных артерий ≥20% по классификации J.A. Rumberger и соавт. у 8 (40%) пациентов с БДПК и у 5 (25%) – с ОА. Сывороточный уровень остеопротегерина был статистически значимо выше у пациентов с КИ≥27 по классификации J.A. Rumberger и соавт. (р=0,04). Кальцификация была выявлена у 9 (56%) из 16 пациентов, имевших уровень витамина D сыворотки &lt;30 нг/мл и у 8 (33%) из 24 пациентов с уровнем витамина D &gt;30 нг/мл.</p></sec><sec><title>Выводы</title><p>Выводы. У пациентов с исходно низким сердечно-сосудистым риском частота сердечно-сосудистой кальцификации при БДПК составляет 45%, при ОА – 40%. Факторы риска коронарной кальцификации у пациентов с БДПК и ОА должны быть изучены дополнительно.</p></sec></abstract><trans-abstract xml:lang="en"><p>The frequency of vascular calcification in patients with osteoarthritis (OA) and calcium pyrophosphate crystal deposition disease (CPPD) has not yet been studied, and the role of calcium crystals (basic and pyrophosphates) in the development of calcification is also unknown.</p><sec><title>Objective</title><p>Objective. Determine the presence and degree of calcification of the coronary vessels in patients with calcium pyrophosphate crystal deposition disease and osteoarthritis of the knee joints with no clinical signs of cardiovascular diseases.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. One-stage, single-center study, performed by the “case – control” method. The main group – 20 patients with CPPD, the comparison group – 20 patients with OA of the knee joints. Inclusion criteria: age from 18 to 65 years; absence of clinical signs of cardiovascular disease at the time of examination and indications of a history of cardiovascular accidents. Exclusion criteria: unsigned informed consent; pregnancy; breastfeeding; other rheumatic disease; cancer; high and very high cardiovascular risk on the SCORE scale. The survey included an assessment of anthropometric data, blood pressure (BP), lipid profile, serum levels of glucose, creatinine, uric acid, C-reactive protein, vitamin D, osteoprotegerin, parathyroid hormone, and the levels of magnesium, phosphorus, and total calcium were studied. All patients underwent multispiral computed tomography with determination of calcium count and the number of affected arteries. To calculate the coronary score, the A.S. Agatston et al.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. Most of the parameters in the compared groups did not differ. When assessing the calcification of the coronary arteries according to the A.S. Agatston et al. 9 (45%) patients with CPPD and 8 (40%) patients with OA had a coronary calcium score &gt;1. Quantitative indicators of calcium score can correspond to coronary artery stenosis ≥20% in 8 (40%) patients with CPPD and in 5 (25%) patients with OA according to J.A. Rumberger et al. The serum level of osteoprotegerin was significantly higher in patients with a calcium score ≥27 according to J.A. Rumberger et al. (p=0.04). Calcification was detected in 9 (56%) of 16 patients with serum vitamin D levels &lt;30 ng/ml and in 8 (33%) of 24 patients with serum vitamin D levels &gt;30 ng/ml.</p></sec><sec><title>Conclusions</title><p>Conclusions. In patients with an initially low cardiovascular risk, the probability of a combination of chondrocalcinosis and cardiovascular calcification is 45%, in OA it is 40%. The risk factors for coronary calcification in patients with CPPD and OA should be studied further.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>болезнь депонирования кристаллов пирофосфата кальция</kwd><kwd>остеоартрит</kwd><kwd>кальциевый индекс</kwd><kwd>кальцификация сосудов</kwd><kwd>С-реактивный белок</kwd><kwd>витамин D</kwd><kwd>остеопротегерин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>calcium pyrophosphate crystal deposition disease</kwd><kwd>osteoarthritis</kwd><kwd>calcium index</kwd><kwd>vascular calcification</kwd><kwd>C-reactive protein</kwd><kwd>vitamin D</kwd><kwd>osteoprotegerin</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Rosenthal AK, Ryan LM. Calcium pyrophosphate deposition disease. N Engl J Med. 2016;374(26):2575-2584. doi: 10.1056/NEJMra1511117</mixed-citation><mixed-citation xml:lang="en">Rosenthal AK, Ryan LM. Calcium pyrophosphate deposition disease. N Engl J Med. 2016;374(26):2575-2584. doi: 10.1056/NEJMra1511117</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Richette P, Bardin T, Doherty M. An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease. Rheumatology. 2009;48(7):711-715. doi: 10.1093/rheumatology/kep081</mixed-citation><mixed-citation xml:lang="en">Richette P, Bardin T, Doherty M. An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease. Rheumatology. 2009;48(7):711-715. doi: 10.1093/rheumatology/kep081</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Abhishek A. Calcium pyrophosphate deposition disease: a review of epidemiologic findings. Curr Opin Rheum. 2016;28(2):133-139. doi: 10.1097/BOR.0000000000000246</mixed-citation><mixed-citation xml:lang="en">Abhishek A. Calcium pyrophosphate deposition disease: a review of epidemiologic findings. Curr Opin Rheum. 2016;28(2):133-139. doi: 10.1097/BOR.0000000000000246</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Fuerst M, Bertrand J, Lammers L, Dreier R, Echtermeyer F, Nitschke Y, et al. Calcification of articular cartilage in human osteoarthritis. Arthritis Rheum. 2009;60:2694-2703. doi: 10.1002/art.24774</mixed-citation><mixed-citation xml:lang="en">Fuerst M, Bertrand J, Lammers L, Dreier R, Echtermeyer F, Nitschke Y, et al. Calcification of articular cartilage in human osteoarthritis. Arthritis Rheum. 2009;60:2694-2703. doi: 10.1002/art.24774</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hawellek T, Hubert J, Hischke S, Vettorazzi E, Wegscheider K, Bertrand J, et al. Articular cartilage calcification of the humeral head is highly prevalent and associated with osteoarthritis in the general population. J Orthop Res. 2016;34:1984-1990. doi: 10.1002/jor.23227</mixed-citation><mixed-citation xml:lang="en">Hawellek T, Hubert J, Hischke S, Vettorazzi E, Wegscheider K, Bertrand J, et al. Articular cartilage calcification of the humeral head is highly prevalent and associated with osteoarthritis in the general population. J Orthop Res. 2016;34:1984-1990. doi: 10.1002/jor.23227</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ea HK, Uzan B, Rey C, Lioté F. Octacalcium phosphate crystals directly stimulate expression of inducible nitric oxide synthase through p38 and JNK mitogen-activated protein kinases in articular chondrocytes. Arthritis Res Ther. 2005;7(5):R915-R926. doi: 10.1186/ar1763</mixed-citation><mixed-citation xml:lang="en">Ea HK, Uzan B, Rey C, Lioté F. Octacalcium phosphate crystals directly stimulate expression of inducible nitric oxide synthase through p38 and JNK mitogen-activated protein kinases in articular chondrocytes. Arthritis Res Ther. 2005;7(5):R915-R926. doi: 10.1186/ar1763</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Thouverey C, Bechkoff G, Pikula S, Buchet R. Inorganic pyrophosphate as a regulator of hydroxyapatite or calcium pyrophosphate dihydrate mineral deposition by matrix vesicles. Osteoarthritis Cartilage. 2009;17:64-72. doi: 10.1016/j.joca.2008.05.020</mixed-citation><mixed-citation xml:lang="en">Thouverey C, Bechkoff G, Pikula S, Buchet R. Inorganic pyrophosphate as a regulator of hydroxyapatite or calcium pyrophosphate dihydrate mineral deposition by matrix vesicles. Osteoarthritis Cartilage. 2009;17:64-72. doi: 10.1016/j.joca.2008.05.020</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Abhishek A, Doherty S, Maciewicz R, Muir K, Zhang W, Doherty M. Association between low cortical bone mineral density, soft-tissue calcification, vascular calcification and chondrocalcinosis: A case-control study. Ann Rheum Dis. 2014;73(11):1997-2002. doi: 10.1136/annrheumdis-2013-203400</mixed-citation><mixed-citation xml:lang="en">Abhishek A, Doherty S, Maciewicz R, Muir K, Zhang W, Doherty M. Association between low cortical bone mineral density, soft-tissue calcification, vascular calcification and chondrocalcinosis: A case-control study. Ann Rheum Dis. 2014;73(11):1997-2002. doi: 10.1136/annrheumdis-2013-203400</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Zazzeroni L, Faggioli G, Pasquinelli G. Mechanisms of arterial calcification: The role of matrix vesicles. Eur J Vasc Endovasc Surg. 2018;55(3):425-432. doi: 10.1016/j.ejvs.2017.12.009</mixed-citation><mixed-citation xml:lang="en">Zazzeroni L, Faggioli G, Pasquinelli G. Mechanisms of arterial calcification: The role of matrix vesicles. Eur J Vasc Endovasc Surg. 2018;55(3):425-432. doi: 10.1016/j.ejvs.2017.12.009</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Shao JS, Cheng SL, Sadhu J, Towler DA. Inflammation and the osteogenic regulation of vascular calcification: a review and perspective. Hypertension. 2010;55(3):579-592. doi: 10.1161/HYPERTENSIONAHA.109.134205</mixed-citation><mixed-citation xml:lang="en">Shao JS, Cheng SL, Sadhu J, Towler DA. Inflammation and the osteogenic regulation of vascular calcification: a review and perspective. Hypertension. 2010;55(3):579-592. doi: 10.1161/HYPERTENSIONAHA.109.134205</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao G, Xu MJ, Zhao MM, Dai XY, Kong W, Wilson GM, et al. Activation of nuclear factor-kappa B accelerates vascular calcification by inhibiting ankylosis protein homolog expression. Kidney Int. 2012;82(1):34-44. doi: 10.1038/ki.2012.40</mixed-citation><mixed-citation xml:lang="en">Zhao G, Xu MJ, Zhao MM, Dai XY, Kong W, Wilson GM, et al. Activation of nuclear factor-kappa B accelerates vascular calcification by inhibiting ankylosis protein homolog expression. Kidney Int. 2012;82(1):34-44. doi: 10.1038/ki.2012.40</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Mitton-Fitzgerald E, Gohr CM, Bettendorf B, Rosenthal AK. The role of ANK in calcium pyrophosphate deposition disease. Curr Rheumatol Rep. 2016;18(5):25. doi: 10.1007/s11926-016-0574-z</mixed-citation><mixed-citation xml:lang="en">Mitton-Fitzgerald E, Gohr CM, Bettendorf B, Rosenthal AK. The role of ANK in calcium pyrophosphate deposition disease. Curr Rheumatol Rep. 2016;18(5):25. doi: 10.1007/s11926-016-0574-z</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Karaali E, Çiloğlu O, Yücel C, Ekiz T. The relationship between primary knee osteoarthritis and aortic stiffness, distensibility, and valve calcifications: A case-control study. J Clin Rheumatol. 2020;10.1097/RHU.0000000000001568. doi: 10.1097/RHU.0000000000001568</mixed-citation><mixed-citation xml:lang="en">Karaali E, Çiloğlu O, Yücel C, Ekiz T. The relationship between primary knee osteoarthritis and aortic stiffness, distensibility, and valve calcifications: A case-control study. J Clin Rheumatol. 2020;10.1097/RHU.0000000000001568. doi: 10.1097/RHU.0000000000001568</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827-832. doi: 10.1016/0735-1097(90)90282-T</mixed-citation><mixed-citation xml:lang="en">Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827-832. doi: 10.1016/0735-1097(90)90282-T</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Rumberger JA, Brundage BH, Rader DJ, Kondos G. Electron beam computed tomographic coronary calcium scanning: A review and guidelines for use in asymptomatic persons. Mayo Clin Proc. 1999 Mar;74(3):243-252. doi: 10.4065/74.3.243</mixed-citation><mixed-citation xml:lang="en">Rumberger JA, Brundage BH, Rader DJ, Kondos G. Electron beam computed tomographic coronary calcium scanning: A review and guidelines for use in asymptomatic persons. Mayo Clin Proc. 1999 Mar;74(3):243-252. doi: 10.4065/74.3.243</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Tinggaard AB, de Thurah A, Andersen IT, Riis AH, Therkildsen J, Winther S, et al. Rheumatoid arthritis as a risk factor for coronary artery calcification and obstructive coronary artery disease in patients with chest pain: A registry based crosssectional study. Clin Epidemiol. 2020;12:679-689. doi: 10.2147/CLEP.S251168</mixed-citation><mixed-citation xml:lang="en">Tinggaard AB, de Thurah A, Andersen IT, Riis AH, Therkildsen J, Winther S, et al. Rheumatoid arthritis as a risk factor for coronary artery calcification and obstructive coronary artery disease in patients with chest pain: A registry based crosssectional study. Clin Epidemiol. 2020;12:679-689. doi: 10.2147/CLEP.S251168</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Vladimirov S, Kudaeva F, Kudinsky D, Smirnov A, Eliseev M. Radiographic progression of knee osteoarthritis in patients with different clinical types of calcium pyrophosphate deposition disease vs patients with osteoarthritis (preliminary data). Ann Rheum Dis. 2017;74:536. doi: 10.1136/annrheumdis-2015-eular.3781</mixed-citation><mixed-citation xml:lang="en">Vladimirov S, Kudaeva F, Kudinsky D, Smirnov A, Eliseev M. Radiographic progression of knee osteoarthritis in patients with different clinical types of calcium pyrophosphate deposition disease vs patients with osteoarthritis (preliminary data). Ann Rheum Dis. 2017;74:536. doi: 10.1136/annrheumdis-2015-eular.3781</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Yiu KH, Wang S, Mok MY, Ooi GC, Khong PL, Mak KF, et al. Pattern of arterial calcification in patients with systemic lupus erythematosus. J Rheumatol. 2009;36(10):2212-2217. doi: 10.3899/jrheum.090312</mixed-citation><mixed-citation xml:lang="en">Yiu KH, Wang S, Mok MY, Ooi GC, Khong PL, Mak KF, et al. Pattern of arterial calcification in patients with systemic lupus erythematosus. J Rheumatol. 2009;36(10):2212-2217. doi: 10.3899/jrheum.090312</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Hwang IC, Park HE, Kim HL, Kim HM, Park JB, Yoon YE, et al. Systemic inflammation is associated with coronary artery calcification and all-cause mortality in chronic kidney disease. Circ J. 2016;80(7):1644-1652. Doi: 10.1253/circj.CJ-15-1224</mixed-citation><mixed-citation xml:lang="en">Hwang IC, Park HE, Kim HL, Kim HM, Park JB, Yoon YE, et al. Systemic inflammation is associated with coronary artery calcification and all-cause mortality in chronic kidney disease. Circ J. 2016;80(7):1644-1652. Doi: 10.1253/circj.CJ-15-1224</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Tarcin O, Yavuz DG, Ozben B, Telli A, Ogunc AV, Yuksel M, et al. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab. 2009;94(10):4023-4030. doi: 10.1210/jc.2008-1212</mixed-citation><mixed-citation xml:lang="en">Tarcin O, Yavuz DG, Ozben B, Telli A, Ogunc AV, Yuksel M, et al. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab. 2009;94(10):4023-4030. doi: 10.1210/jc.2008-1212</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Yashiro T, Okamoto T, Tanaka R, Ito K, Hara H, Yamashita T, et al. Prevalence of chondrocalcinosis in patients with primary hyperparathyroidism in Japan. Endocrinol Jpn. 1991;38(5):457-464. doi: 10.1507/endocrj1954.38.457</mixed-citation><mixed-citation xml:lang="en">Yashiro T, Okamoto T, Tanaka R, Ito K, Hara H, Yamashita T, et al. Prevalence of chondrocalcinosis in patients with primary hyperparathyroidism in Japan. Endocrinol Jpn. 1991;38(5):457-464. doi: 10.1507/endocrj1954.38.457</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Terai K, Nara H, Takakura K, Mizukami K, Sanagi M, Fukushima S, et al. Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels. Br J Pharmacol. 2009;156(8):1267-1278. doi: 10.1111/j.1476-5381.2008.00108.x</mixed-citation><mixed-citation xml:lang="en">Terai K, Nara H, Takakura K, Mizukami K, Sanagi M, Fukushima S, et al. Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels. Br J Pharmacol. 2009;156(8):1267-1278. doi: 10.1111/j.1476-5381.2008.00108.x</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Colak S, Aydogan BI, Gokcay Canpolat A, Tulunay Kaya C, Sahin M, Corapcioglu D, et al. Is primary hyperparathyroidism a cause of endothelial dysfunction? Clin Endocrinol (Oxf). 2017;87(5):459-465. doi: 10.1111/cen.13418</mixed-citation><mixed-citation xml:lang="en">Colak S, Aydogan BI, Gokcay Canpolat A, Tulunay Kaya C, Sahin M, Corapcioglu D, et al. Is primary hyperparathyroidism a cause of endothelial dysfunction? Clin Endocrinol (Oxf). 2017;87(5):459-465. doi: 10.1111/cen.13418</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Tschiderer L, Willeit J, Schett G, Kiechl S, Willeit P. Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants. PLoS One. 2017;12(8):e0183910. doi: 10.1371/journal.pone.0183910</mixed-citation><mixed-citation xml:lang="en">Tschiderer L, Willeit J, Schett G, Kiechl S, Willeit P. Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants. PLoS One. 2017;12(8):e0183910. doi: 10.1371/journal.pone.0183910</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Beyazal MS, Erdoğan T, Devrimsel G, Türkyılmaz AK, Cüre MC, Beyazal M, et al. Relationship of osteoprotegerin to pulse wave velocity and carotid intima-media thickness in rheumatoid arthritis patients. Z Rheumatol. 2016;75(7):723-728. doi: 10.1007/s00393-015-1675-1</mixed-citation><mixed-citation xml:lang="en">Beyazal MS, Erdoğan T, Devrimsel G, Türkyılmaz AK, Cüre MC, Beyazal M, et al. Relationship of osteoprotegerin to pulse wave velocity and carotid intima-media thickness in rheumatoid arthritis patients. Z Rheumatol. 2016;75(7):723-728. doi: 10.1007/s00393-015-1675-1</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
